Welcome to the world of Micreos...
Bacteria are all around us. Most of them are good and protect us, but some can cause irritation or infection. Antibiotics do not distinguish between good and bad bacteria and their use can lead to side effects and resistance. This renders them unsuitable for long-term use. As they have been broadly used - often inappropriately - the emergence of antibiotic-resistant 'superbugs' is now a global concern. On the other hand it has become evident that our microbiome, comprising billions of beneficial bacteria, is necessary for our health and should be left intact.
Micreos develops the world's first targeted antibacterial products, set to replace antibiotics. The company is viewed as global leader spearheading this exciting new field. With Micreos endolysin technology, for the first time we can kill only the unwanted bacteria - including antibiotic resistant strains - while preserving the beneficial bacteria, essential for our health. In addition, scientists do not expect emergence of resistance against endolysins, based on their working mechanism. This unlocks a completely new approach in dealing with the bacteria around us - also enabling preventive daily therapy against only unwanted bacteria for as long as needed.
Micreos' Staphefekt SA.100 is an enzyme (endolysin), which kills only Staphylococcus aureus, including MRSA. It is suitable for daily maintenance therapy, for inflammatory skin conditions such as eczema, rosacea, psoriasis and inflammatory acne and has already had a life changing impact for thousands of people. It is marketed under the Gladskin brand. For further background information on SA.100 fact sheets are available. Micreos next generation endolysin, XZ.700, is in clinical development for global registration as a pharmaceutical product. Atopic dermatitis is the first targeted indication. A combined Phase I/II trial is planned to start in 2018. It is preceded by a randomised controlled Gladskin Eczema trial with SA.100, at Erasmus Medical Centre, set to be concluded by early 2018.
Under the Phageguard brand Micreos has also developed FDA-approved food safety products against Salmonella and Listeria monocytogenes, which is especially dangerous for pregnant women and for the elderly and immuno-compromised. More information on these food safety products is available at the Phageguard website
The company is committed to helping mankind with products that are effective, sustainable and affordable. The company's products:
- work fast
- are easy to apply
- have no known adverse effects
Micreos' technology is applied in many areas, including human health, food safety, animal health and agriculture. Micreos Human Health is based in Bilthoven at the RIVM premises (Dutch NIH). Micreos Food Safety is based in Wageningen 'Food Valley'. Micreos headquarters are based in The Hague, world capital of Peace and Justice.
Micreos runs a modern Endolysin and Phage Technology Centre, responsible for Production, Research & Development, and Quality Control. We work according to the highest ethical and professional standards, as witnessed by numerous awards and grants received over the past years, and publications in scientific journals and regular press. Micreos collaborates with top institutes and companies around the world and its advisors and partners have broad expertise in the fields in which we operate. Our long-term research partners include ETH Zurich, Switzerland, (Prof. Loessner) and Erasmus Medical Center Rotterdam (Prof. Pasmans, pediatric dermatology).